Stock JNJ JOHNSON & JOHNSON
Add to a list
To use this feature you must be a member
Log inSign up

Johnson & Johnson Stock

Equities

JNJ

US4781601046

Pharmaceuticals

Market Closed - Nyse
Other stock markets
 04:00:02 2025-01-17 pm EST 		5-day change 1st Jan Change
147.03 USD -0.50% Intraday chart for Johnson & Johnson +1.77% +1.67%
Jan. 20 Sumitomo Pharma Co., Ltd. Announces Agreement on Co-Promotion Collaboration Partner for Marketing of Pplat Xeplion and Xeplion Trial in Japan with Johnson & Johnson CI
Jan. 17 S&P 500 Logs 2.9% Weekly Gain on Easing Inflationary Pressures, Strong Bank Earnings MT

Valuation: Johnson & Johnson

Capitalization 354B 340B 321B 288B 507B 30,518B 565B 3,904B 1,447B 12,590B 1,328B 1,300B 55,106B P/E ratio 2024 *
21.2x
P/E ratio 2025 * 17x
Enterprise value 365B 351B 332B 297B 523B 31,489B 583B 4,029B 1,493B 12,991B 1,370B 1,342B 56,859B EV / Sales 2024 *
4.11x
EV / Sales 2025 * 3.85x
Free-Float
77.09%
Yield 2024 *
3.24%
Yield 2025 * 3.41%
More valuation ratios * Estimated data

Chart: Johnson & Johnson

Dynamic Chart

Latest news: Johnson & Johnson

Sumitomo Pharma Co., Ltd. Announces Agreement on Co-Promotion Collaboration Partner for Marketing of Pplat Xeplion and Xeplion Trial in Japan with Johnson & Johnson Jan. 20 CI
S&P 500 Logs 2.9% Weekly Gain on Easing Inflationary Pressures, Strong Bank Earnings Jan. 17 MT
Johnson & Johnson Q4 EPS, Revenue Estimates Nudged Higher, BofA Says Jan. 17 MT
BofA Securities Adjusts Johnson & Johnson Price Target to $160 From $166, Maintains Neutral Rating Jan. 17 MT
Johnson & Johnson Announces RYBREVANT Plus Chemotherapy Approved in Canada as First and Only Targeted Treatment to Reduce Risk of Disease Progression or Death by More Than Half in Second-Line Egfr-Mutated Advanced Lung Cancer Jan. 16 CI
Johnson & Johnson: FDA to review TAR-200 dossier Jan. 15 CF
J&J Initiates Bid for FDA Approval of TAR-200 in Bladder Cancer Jan. 15 DJ
Johnson & Johnson Submits New Drug Application for TAR-200 Drug-Releasing System for Bladder Cancer Jan. 15 MT
Johnson & Johnson Initiates the Submission of an Original New Drug Application with the U.S. Food and Drug Administration for TAR-200 for the Treatment of Patients with Bacillus Calmette-Guerinvasive Bladder Cancer Jan. 15 CI
Formycon, Fresenius Kabi Secure UK Medicines Regulator's Nod for Stelara Biosimilar Jan. 15 MT
Sector Update: Health Care Stocks Slide Late Afternoon Jan. 14 MT
Sector Update: Health Care Jan. 14 MT
Johnson & Johnson Ratings Put On CreditWatch Negative by S&P Global Jan. 14 MT
More news

Last Transcript: Johnson & Johnson

Logo Johnson & Johnson
Johnson & Johnson Presents at 43rd Annual J.P. Morgan Healthcare Conference 2025, Jan-13-2025 09:00 AM
Jan. 13
More transcripts

Analysts' recommendations: Johnson & Johnson

BofA Securities Adjusts Johnson & Johnson Price Target to $160 From $166, Maintains Neutral Rating Jan. 17 MT
Goldman Sachs Adjusts Price Target on Johnson & Johnson to $158 From $159, Keeps Neutral Rating Jan. 10 MT
Bernstein Adjusts Price Target on Johnson & Johnson to $160 From $177, Maintains Market Perform Rating Jan. 08 MT
Citigroup Adjusts Price Target on Johnson & Johnson to $175 From $185, Keeps Buy Rating Dec. 11 MT
J&J: positive CHMP opinion for Lazcluze in lung cancer Nov. 18 CF
More recommendations

Press Releases: Johnson & Johnson

RYBREVANT® plus chemotherapy approved in Canada as first and only targeted treatment to reduce risk of disease progression or death by more than half in second-line EGFR-mutated advanced lung cancer Jan. 16 AQ
New Drug Application initiated with U.S. FDA for TAR-200, the first and only intravesical drug releasing system for patients with BCG-unresponsive high-risk non-muscle-invasive bladder cancer Jan. 15 PR
J&J buys Intra-Cellular in $14.6 billion deal, delving further into central nervous system disorders Jan. 13 AQ
Johnson & Johnson Strengthens Neuroscience Leadership with Acquisition of Intra-Cellular Therapies, Inc. Jan. 13 BU
Johnson & Johnson : MedTech Announces CE Mark Approval for Dual Energy THERMOCOOL SMARTTOUCH™ SF Catheter Jan. 10 PU
More press releases

News in other languages: Johnson & Johnson

Il est de retour, et il est pressé Jan. 20
Donald Trump va donner le "la" sur les marchés Jan. 20
Johnson & Johnson : la FDA va examiner le dossier TAR-200 Jan. 15
MÄRKTE USA/Wall Street mit Erholungsbewegung Jan. 13
MÄRKTE USA/Wall Street von andauernden Zinssorgen belastet Jan. 13
More news

Quotes and Performance

1 day-0.50%
1 week+1.77%
Current month+1.67%
1 month+1.77%
3 months-10.96%
6 months-4.95%
Current year+1.67%
More quotes

Course Extremes

1 week
144.06
Extreme 144.06
148.38
1 month
140.68
Extreme 140.68
148.38
Current year
140.68
Extreme 140.68
148.38
1 year
140.68
Extreme 140.68
168.85
3 years
140.68
Extreme 140.68
186.69
5 years
109.16
Extreme 109.16
186.69
10 years
81.79
Extreme 81.79
186.69
More quotes

Managers and Directors: Johnson & Johnson

Director TitleAgeSince
Joaquin Duato CEO
 Chief Executive Officer 62 2022-01-02
Joseph Wolk DFI
 Director of Finance/CFO 58 2018-06-30
William Hait CTO
 Chief Tech/Sci/R&D Officer 75 2021-12-31
Manager TitleAgeSince
Anne Mulcahy BRD
 Director/Board Member 71 2009-10-22
Mark McClellan BRD
 Director/Board Member 61 2013-10-14
Mary Beckerle BRD
 Director/Board Member 70 2015-06-08
More insiders

ETFs: Johnson & Johnson

Name Weight AuM 1st Jan change Investor Rating
AGF U.S. MARKET NEUTRAL ANTI-BETA FUND - USD ETF AGF U.S. Market Neutral Anti-Beta Fund - USD
14.01% 335 M€ -2.98% -
NOMURA NEXT FUNDS INTERNATIONAL EQUITY MSCI-KOKUSAI (YEN-HEDGED) ETF - JPY ETF Nomura NEXT FUNDS International Equity MSCI-KOKUSAI (Yen-Hedged) ETF - JPY
12.91% 30 M€ +1.14% -
More ETFs: Johnson & Johnson

Other Pharmaceuticals

Add to a list
Add to a list

0 selected

To use this feature you must be a member
Log inSign up
 Change 5d. change 1-year change 3-years change Capi. ($)
JOHNSON & JOHNSON Stock Johnson & Johnson
-0.50%+1.77%-9.06%-11.03%354B
ELI LILLY AND COMPANY Stock Eli Lilly and Company
-4.21%-9.00%+15.45%+198.49%653B
NOVO NORDISK A/S Stock Novo Nordisk A/S
-4.22%-10.08%-24.73%+73.23%341B
ABBVIE INC. Stock AbbVie Inc.
-1.23%-2.93%+4.12%+28.96%303B
MERCK & CO., INC. Stock Merck & Co., Inc.
-2.76%-3.03%-17.64%+21.26%248B
ROCHE HOLDING AG Stock Roche Holding AG
+0.57%+0.76%+9.34%-26.90%236B
ASTRAZENECA PLC Stock AstraZeneca PLC
-1.32%-0.26%+2.72%+22.08%206B
NOVARTIS AG Stock Novartis AG
-0.10%-1.72%-4.87%+9.63%197B
PFIZER, INC. Stock Pfizer, Inc.
-0.72%-1.87%-7.00%-51.34%149B
AMGEN INC. Stock Amgen Inc.
+0.99%+0.71%-11.60%+18.88%146B
Average -1.35%-1.83%-4.33%+28.33% 283.38B
Weighted average by Cap. -1.96%-3.21%-1.98%+56.47%
See all sector performances

Financials

2024 *2025 *
Net sales 88.78B 85.37B 80.59B 72.18B 127B 7,653B 142B 979B 363B 3,157B 333B 326B 13,820B 91.06B 87.56B 82.66B 74.03B 130B 7,850B 145B 1,004B 372B 3,239B 342B 334B 14,175B
Net income 17.5B 16.82B 15.88B 14.22B 25.05B 1,508B 27.94B 193B 71.51B 622B 65.62B 64.26B 2,724B 20.77B 19.97B 18.85B 16.89B 29.74B 1,790B 33.17B 229B 84.89B 739B 77.89B 76.29B 3,233B
Net Debt 11.26B 10.83B 10.22B 9.15B 16.12B 971B 17.98B 124B 46.03B 400B 42.23B 41.36B 1,753B -3.43B -3.3B -3.11B -2.79B -4.91B -296B -5.47B -37.81B -14.01B -122B -12.86B -12.59B -534B
More financial data * Estimated data

Company Profile

Logo Johnson & Johnson
Johnson & Johnson is one of the world's leading producers of healthcare products. Net sales break down by family of products as follows: - pharmaceutical products (64.3%): drugs intended for the treatment of cardiovascular diseases, oncological diseases, gastro-intestinal illnesses, infectious, immunological, neurological, dermatological diseases, etc.; - medical products and equipment (35.7%): diagnostic systems, orthopedic and gynecological equipment, surgical materials, etc. for use by healthcare professionals; At the end of 2023, Johnson & Johnson has 61 manufacturing facilities located in the United States (23), North America (5), Europe (20), Africa and Asia/Pacific (13). The United States accounts for 54.5% of net sales.
Employees
131,900
Sector
Pharmaceuticals
Calendar
2025-01-22 - Q4 2024 Earnings Release
More about the company

Quotes

Date Price Change Volume
25-01-17 147.03 $ -0.50% 10,773,054
25-01-16 147.77 $ +1.93% 8,964,016
25-01-15 144.97 $ +0.15% 7,434,562
25-01-14 144.75 $ +0.19% 8,681,741

Delayed Quote Nyse, January 17, 2025 at 04:00 pm EST

More quotes

Income Statement and Estimates

income-statement-evolution-chart JOHNSON-JOHNSON More financial data

Ratings

Trading Rating
Investor Rating
ESG MSCI
A
surperformance-ratings-light-chart JOHNSON-JOHNSONMore Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
23
Last Close Price
147.03USD
Average target price
171.34USD
Spread / Average Target
+16.53%
Consensus
Profit revisions
estimates-change-chart JOHNSON-JOHNSON Estimate revisions

Quarterly revenue - Rate of surprise

quality-estimates-chart JOHNSON-JOHNSON Company calendar
  1. Stock Market
  2. Equities
  3. JNJ Stock